Single versus double lung transplantation in pulmonary fibrosis: a debated topic.
Idiopathic pulmonary fibrosis (IPF) represents the second most frequent indication for lung transplantation after chronic obstructive pulmonary disease. Survival rate after transplantation is poorer compared with other lung diseases for reasons that are not completely clear. Medical therapy with anti-inflammatory drugs may improve symptoms and quality of life, but it does not influence the survival rate. Lung transplantation is the best therapy for end-stage IPF. The debate regarding the superiority of double lung transplantation (DLT) compared with single lung transplantation (SLT) is still ongoing. Until some years ago, SLT was almost uniformly utilized for this indication. In the most recent years, a larger application of DLT has been observed worldwide, probably related to higher 1-year and 5-year survivals. The unanswered question is whether it is ethical to use two lungs for the same patient, considering the donor shortage, when a single lung would suffice. Many reports have demonstrated that SLT offers acceptable pulmonary function and satisfactory early and intermediate survival. Probably DLT should be reserved for younger recipients, for those with concomitant or possible chronic infection of the contralateral lung, or cases of marginal donors. Further studies will be needed to formulate recommendations regarding the preferred surgical approach in IPF.
Rinaldi
M
M
Division of Cardiac Surgery, University of Turin, S. Giovanni Battista Hospital, Turin, Italy.
Sansone
F
F
Boffini
M
M
El Qarra
S
S
Solidoro
P
P
Cavallo
N
N
Ruffini
E
E
Baldi
S
S
D000328:Adult; D007839:Functional Laterality; D006801:Humans; D016040:Lung Transplantation / Q000379:methods* / Q000401:mortality; D011658:Pulmonary Fibrosis / Q000453:epidemiology / Q000401:mortality / Q000601:surgery*; D040841:Resource Allocation; D014019:Tissue Donors / Q000706:statistics & numerical data; D016896:Treatment Outcome